Category:
Definition & Diagnosis
Ductal Carcinoma In Situ of the Breast
Major advances in the detection of carcinoma of the breast have occurred in the past several decades. The increased use of mammography for screening and early detection has resulted in a significant increase in the diagnosis of early breast cancer and specifically ductal carcinoma in situ (DCIS).
|
.not dated |
Category:
Medical Studies
When to recommend and to pay for first-line adjuvant breast cancer treatment? A structured review of
A structured review of studies on the health-economic evaluation of systemic adjuvant therapy for early-stage breast cancer was carried out. Of the eight articles that have been identified four were related to the cost-effectiveness of chemotherapy, three compared chemotherapy with combined chemotherapy and hormonal therapy and one compared tamoxifen (TAM) with third-generation aromatase inhibitors (ATIs).
|
1992/06/15 |
Category:
Medical Studies
Therapies for DCIS - List
Results of search at PubMed
|
.not dated |
Category:
Medical Studies
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women
For endocrine therapy of hormone-sensitive advanced breast cancer in postmenopausal women, the third-generation aromatase inhibitors, letrozole, anastrozole, and exemestane, are effective both as alternatives to tamoxifen in first-line treatment and following first-line tamoxifen failure.
|
1992/02/15 |
Category:
Medical Studies
Sentinel Lymph Node Biopsy: Questions and Answers
A sentinel lymph node (SLN) is the first lymph node(s) to which cancer cells are likely to spread from the primary tumor. Cancer cells may appear in the sentinel node before spreading to other lymph nodes (see Question 2).
SLN biopsy can be used to help determine the extent or stage of cancer (see Question 3).
|
2003-2004 various |
Category:
Miscellaneous
BC Cancer Agency
Site Home - British Columbia Cancer Agency
|
|
Category:
Definition & Diagnosis
Drug Index (Professional) - Anastrozole
Anastrozole is a reversible (Type II), nonsteroidal aromatase inhibitor. Aromatase catalyzes the final and rate-limiting step in the conversion of androgens to estrogens in peripheral tissues.
|
.multiple date refs |
Category:
Miscellaneous
Legal Aspects of Cancer
Today, the physician who works to diagnose or treat cancer has a difficult dilemma. The patients’ expectations regarding the discovery and cure of their disease often are at odds with the realities of cancer.
|
.not dated |
Category:
Medical Studies
An interim analysis of a prospective multi-institutional cohort study: quantitative real-time RT-PCR
The clinical relevance of molecular detection of micrometastatic breast cancer in sentinel and axillary lymph nodes has not been established.
|
2003/12/03 |
Category:
Medical Studies
Micrometastases in sentinel lymph nodes of patients with ductal carcinoma in situ of the breast have
Background: (Micro-)metastases may be detected in sentinel axillary lymph nodes of patients with in situ carcinoma or small invasive carcinomas of the breast. For some surgeons this is a reason to routinely perform a sentinel node procedure in situations otherwise known to have an excellent prognosis without axillary staging. The incidence and predictive value of these positive nodes is uncertain.
|
2003/12/03 |
Category:
Medical Studies
Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial acc
Background: The ATAC trial randomized 9366 postmenopausal women with early breast cancer to 5 years of treatment with anastrozole (A) or tamoxifen (T) or the combination (C) of A+T. After 47 months median follow-up the hazard ratio (HR) for disease-free survival was 0.86 (0.760.99, p=0.03) in the overall population and 0.82 (0.700.96, p=0.014) in the estrogen receptor (ER) and/or progesterone receptor (PgR) positive group, in favor of A when compared with T.
|
2003/12/03 |
Category:
Miscellaneous
San Antonio Breast Cancer Symposium
Site Home Free Registration -- The Abstracts2View™-on-Line program is supported by an unrestricted grant from GlaxoSmithKline.
|
2003/12 |
Category:
Medical Studies
Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen
Background: The ATAC trial showed that anastrozole (‘Arimidex’; A) has superior efficacy to tamoxifen (T) as adjuvant therapy in early hormone receptor-positive breast cancer.
|
2003/12/03 |
Category:
Medical Studies
Resistance to endocrine therapy in a xenograft model of HER-2 overexpressing breast cancer is accomp
Breast cancer growth is regulated by estrogen and other steroid hormones as well as peptide growth factors such as EGF and IGF-1. Crosstalk between these signaling pathways may determine patterns of response and resistance to endocrine therapy.
|
2003/12/03 |
Category:
Definition & Diagnosis
Ductal Carcinoma in Situ (DCIS)
The American Cancer Society estimates that 41,000 news cases of ductal carcinoma in situ (also called DCIS or intraductal carcinoma) will be diagnosed in 2000, making DCIS the most common type of non-invasive breast cancer in women. DCIS accounts for nearly 25% of all breast cancer diagnoses.
|
2005 |
Category:
Medical Studies
Aromatase Inhibitors in Breast Cancer: An Update
Background: Tamoxifen has been the endocrine treatment of choice for patients with breast cancer. The development of selective aromatase inhibitors has offered an alternative management approach for patients in whom a hormonal approach is indicated.
*Registration Required, Free*
|
2003/02/10 |
Category:
Medical Studies
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cance
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells
|
2005/12/08 |
Category:
Definition & Diagnosis
Ductal carcinoma in Situ (DCIS) Summary Information
DCIS stands for ductal carcinoma in situ. This means that in a part of your breast the cells lining the milk ducts (the channels in the breast that carry milk to the nipple) are cancerous, but stay contained within the ducts without growing through into the surrounding breast tissue. DCIS may affect just one area of the breast but can be more widespread and affect different areas at the same time. Sometimes DCIS may be described as pre-cancerous, pre-invasive, non-invasive or intraductal cancer.
|
2005/11/02 |
Category:
Definition & Diagnosis
What is ductal carcinoma in situ?
Ductal carcinoma in situ (DCIS) is an overgrowth of irregular-looking cells in a duct (the delivery system) of the milk glands of a breast. Sometimes these overgrowths can nearly fill the tiny space within a section of a milk duct. DCIS, which is often called stage 0 cancer or noninvasive cancer, was formerly included in statistics about cancer rates.
|
.not dated |
Category:
Miscellaneous
BreastCancer.org - Breast Cancer Information
Cancer Site
|
.not dated |